Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED]

Trial Profile

CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED]

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CHAARTED
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Aug 2018 Results of pooled data from (CHAARTED and LATITUDE), were published in the Targeted Oncology.
    • 31 Jan 2018 Primary endpoint (Overall Survival) has been met as per the results published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top